Antibody-drug conjugates present and future

mAbs

Volumn 6, Issue 1, 2014, Pages 15-17

  Beck, Alain ^a   Reichert, Janice M ^b  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b Reichert Biotechnology Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; AURISTATIN DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; CYTOTOXIC AGENT; DUOCARMYCIN DERIVATIVE; GEMTUZUMAB OZOGAMICIN; IMMUNOTOXIN; INOTUZUMAB OZOGAMICIN; MAYTANSINOID DERIVATIVE; MONOCLONAL ANTIBODY; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIBODY LIBRARY; BIOENGINEERING; CLINICAL EVALUATION; COMMERCIAL PHENOMENA; DRUG CONJUGATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; EDITORIAL; ELECTROPHORESIS; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HUMAN; LICENSING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICAL TECHNOLOGY; SOLID TUMOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCONJUGATES; MAYTANSINE;

EID: 84892621213     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27436     Document Type: Editorial

References (22)

1. Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329-39; PMID:21034674
2. Reichert JM. Antibodies to watch in 2014. MAbs 2013; 6: In press; PMID:24284914.
3. Wagner-Rousset E, Janin-Bussat MC, Colas O, Excoffier M, Haeuw JF, Rilatt I, Perez M, Corvaïa N, Beck A. Antibody Drug Conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. MAbs 2013; 6: Forthcoming 2013; PMID:24135617.
4. Beck A. Review of Antibody-Drug Conjugates, Methods in Molecular Biology series: A book edited by Laurent Ducry, mAbs 2014; 6: in press.
5. Beck A, Wurch T, Bailly C, Corvaïa N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/ nri2747
6. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26:925-32; PMID:18641636; http://dx.doi.org/10.1038/nbt.1480
7. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012; 30:184-9; PMID:22267010; http://dx.doi.org/10.1038/nbt.2108
8. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs 2014; 6: Forthcoming 2013; http:// dx.doi.org/10.4161/mabs.27022.
9. Behrens CR, Liu B. Methods for site-specific drug conjugation to antibodies. MAbs 2013; 6: In press; PMID:24135651.
10. Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011; 3:161-72; PMID:21441786; http://dx.doi. org/10.4161/mabs.3.2.14960
11. Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier- Cianférani S. Characterization of therapeutic antibodies and related products. Anal Chem 2013; 85:715-36; PMID:23134362; http:// dx.doi.org/10.1021/ ac3032355
12. Rosati S, van den Bremer ET, Schuurman J, Parren PW, Kamerling JP, Heck AJ. In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap. MAbs 2013; 5:917-24; PMID:23995615; http://dx.doi. org/10.4161/mabs.26282
13. Beck A, Senter P, Chari R. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. MAbs 2011; 3:331-7; PMID:21691144; http://dx.doi.org/10.4161/ mabs.3.4.16612
14. Beck A, Lambert J, Sun M, Lin K. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. MAbs 2012; 4:637-47; PMID:22909934; http://dx.doi. org/10.4161/mabs.21697
15. Klinguer-Hamour C, Strop P, Shah DK, Ducry L, Xu A, Beck A. World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs 2014; 6: Forthcoming 2014.
16. Beck A, Hanala S, Reichert JM. 4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland. MAbs 2009; 1:93-103; PMID:20061813; http://dx.doi.org/10.4161/ mabs.1.2.7890
17. Beck A, Reichert JM, Wurch T. 5th European Antibody Congress 2009: November 30-December 2, 2009, Geneva, Switzerland. MAbs 2010; 2:108-28; PMID:20179425; http://dx.doi.org/10.4161/ mabs.2.2.11302
18. Beck A, Wurch T, Reichert JM. 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland. MAbs 2011; 3:111-32; PMID:21441785; http://dx.doi.org/10.4161/ mabs.3.2.14788
19. Lugovskoy AA, Reichert JM, Beck A. 7th Annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. MAbs 2012; 4:134-52; PMID:22453093; http://dx.doi. org/10.4161/mabs.4.2.19426
20. Beck A, Carter PJ, Gerber HP, Lugowskoy AA, Wurch T, Junutula JR, Kontermann K, Mabry R. 8th Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. MAbs 2013; 5:339-57; http://dx.doi.org/10. 4161/ mabs.24105
21. Pauwels PJ, Dumontet C, Reichert JM, Beck A, Goetsch L, Corvaia N, Klein C, Coiffier B, Teicher B. 7th cancer scientific forum of theCancé ropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. MAbs 2012; 4:434-44; PMID:22684281; http://dx.doi.org/10.4161/mabs.20869
22. Ho M, Royston I, Beck A. 2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA. MAbs 2012; 4:562-70; PMID:22864478; http://dx.doi.org/10.4161/ mabs.21521